Tag: dermatology

Click to read the study in the Journal of the American Academy of Dermatology.
Click to read the study in the Journal of the American Academy of Dermatology.
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of PASI90 and IGA response. 2. The safety profile of Bimekizumab was overall mild and similar to current treatment option ustekinumab Evidence Rating Level: 1 (Excellent) Study Rundown: Plaque psoriasis is a chronic...
Click to read the study in the Journal of the American Academy of Dermatology.
1. 91% of patients receiving bimekizumab 320 mg every 4 weeks achieved ≥ 90% improvement from baseline in the Psoriasis Area Severity Index (PASI90) compared to 1% receiving placebo. 2. After achieving PASI90 at week 16, bimekizumab response was maintained through week 56 in both dosing schedules (every 4 weeks...